8-K: Propanc Biopharma Secures $108,000 in Convertible Note Financing to Bolster Working Capital

Propanc Biopharma, Inc. has entered into securities purchase agreements with investors to raise $108,000 through the issuance of convertible promissory notes, aimed at enhancing the company's working capital.

Summary

• Propanc Biopharma, Inc. entered into two securities purchase agreements on February 6, 2025, and February 10, 2025.
• The first agreement involves the issuance of a convertible promissory note with a principal amount of $65,000 to 1800 Diagonal Lending LLC for a purchase price of $56,000.
• This note has a maturity date of November 30, 2025, and includes a one-time interest charge of 15%, resulting in a total payback of $74,750.
• The second agreement involves the issuance of a convertible promissory note with a principal amount of $43,000 to GS Capital Partners, LLC for a purchase price of $40,000.
• This note matures on October 7, 2025, and bears an annual interest rate of 8%.
• The company intends to use the net proceeds from both agreements for general working capital purposes.
• Both notes are convertible into shares of Propanc Biopharma's common stock under certain conditions, including events of default.
• The first note has a conversion price based on 65% of the lowest trading price in the 10 days prior to conversion, while the second note has a fixed conversion price of $9.00 per share, potentially decreasing to $6.00 if the stock trades below $8.00 for five consecutive days.
• The first note includes mandatory monthly payments starting July 30, 2025, while the second note allows for prepayment with premiums during the first 180 days.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the financing provides needed capital, the terms are not particularly favorable, with high interest rates and potential dilution. The company's reliance on this type of financing also suggests potential challenges in accessing more traditional funding sources.

Positives

• The financing provides Propanc Biopharma with additional working capital.
• The company has the right to prepay the second note with a premium during the first 180 days.
• The agreements allow for flexibility in managing debt through potential conversion into common stock.

Negatives

• The notes include events of default that could trigger immediate payment obligations.
• The conversion of the notes could lead to dilution of existing shareholders' equity.
• The company is obligated to maintain a reserve of shares for potential conversion, which could limit its flexibility in managing its capital structure.
• The interest rates on the notes are relatively high, especially the 15% one-time charge on the first note and the 22% default interest rate.

Risks

• Failure to meet payment obligations could trigger events of default and accelerate the debt.
• The company's stock price could be negatively impacted by the potential dilution from the conversion of the notes.
• The company's ability to maintain its listing on the OTC markets is crucial, as delisting would constitute an event of default.
• Breach of covenants or representations could lead to acceleration of the debt and potential legal action.

Future Outlook

The company intends to use the net proceeds from the sale of the notes for general working capital purposes.

Industry Context

Small biopharmaceutical companies often rely on convertible notes to raise capital due to the inherent risks and long development timelines associated with drug development. These notes provide a flexible financing option, but also carry risks related to dilution and debt repayment.

Comparison to Industry Standards

• Convertible notes are a common financing tool for small-cap and micro-cap companies, particularly in the biotech and pharmaceutical sectors.
• The interest rates and conversion terms are within the typical range for such financings, but the specific terms (e.g., the 15% one-time interest charge on the first note) should be evaluated in the context of the company's financial condition and risk profile.
• Comparable companies might include other small biopharma firms listed on the OTC markets that have recently raised capital through similar instruments.
• It's important to compare the conversion terms, interest rates, and other covenants to industry benchmarks to assess the favorability of these agreements for Propanc Biopharma.

Stakeholder Impact

• Shareholders may experience dilution if the notes are converted into common stock.
• Employees may benefit from the increased working capital, which could support ongoing operations.
• Creditors may be impacted by the new debt obligations, potentially affecting the company's creditworthiness.

Next Steps

• The company will use the proceeds for general working capital purposes.
• The company must comply with the terms of the notes, including making timely payments and maintaining its listing on the OTC markets.
• The company needs to monitor its stock price to manage potential conversion scenarios and dilution.

Key Dates